Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer
Despite limitations, this study shows an association between the use of lenvatinib and the development of lipid alterations in patients with advanced thyroid cancer. However, further investigation is necessary for a more comprehensive understanding of the adverse metabolic profile of MKIs.
Authors
- Antonella Verrienti (ORCID: https://orcid.org/0000-0002-3603-5972)
- Giorgio Grani (ORCID: https://orcid.org/0000-0002-0388-1283)
- Elisa Acitelli (ORCID: https://orcid.org/0009-0000-8412-5705)
- Margherita Macera (ORCID: https://orcid.org/0000-0002-6519-3574)
- Cosimo Durante (ORCID: https://orcid.org/0000-0002-1791-5915)
- Valeria Pecce (ORCID: https://orcid.org/0000-0002-5693-2988)
- Marialuisa Sponziello (ORCID: https://orcid.org/0000-0003-0736-1047)
- Marianna Maranghi (ORCID: https://orcid.org/0000-0002-3117-7488)
- Ilenia Minicocci (ORCID: https://orcid.org/0000-0002-9801-4501)
- Samuele Barp
- P Lucia
Institutions
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Endocrine
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1007/s12020-024-04003-y
- Citations
- 2
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.72